ANL — Adlai Nortye Group Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1944552 ·
Singapore
Last close
$15.53
Market Cap
$912.15M
52W High
$17.25
52W Low
$0.88
ADV30
161,853
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 248,362,000 | 132,590,000 | 33,534,000 |
| Dec 2025 | — | — | — | — | 34,433,000 | 8,056,000 | 42,755,000 |
| Jun 2025 | — | — | — | — | 72,045,000 | 44,138,000 | 64,124,000 |
| Dec 2024 | — | — | — | — | 71,270,000 | 60,902,000 | 45,785,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,846,000
Inventory
—
Receivables
$1,390,000
ST Investments
$0
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$18,056,000
EBITDA
$-21,650,500
Free Cash Flow
$-11,449,125
Enterprise Value
$773,376,640
Total Cash
$232,816,992
Total Debt
$26,701,000
Shares Out
58,734,604
Trailing EPS
$-0.66
Book Value
$3.34
ROE
-20.2%
ROA
-8.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,000,000 | -35,698,000 | -35,528,000 | 34,433,000 | 42,755,000 | -8,322,000 | -33,452,000 |
| Dec 2024 | 0 | -52,928,000 | -51,869,000 | 71,270,000 | 45,785,000 | 25,485,000 | -51,819,000 |
| Dec 2023 | 0 | -72,551,000 | -109,228,000 | 130,189,000 | 55,143,000 | 75,046,000 | -56,652,000 |
| Dec 2022 | 0 | -67,270,000 | -58,790,000 | 72,594,000 | 313,887,000 | -241,293,000 | -43,223,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | $917.07M | $14.42 | — |
| ALMS | ALUMIS INC. | $918.99M | $7.10 | — |
| HELP | CYBIN INC. | $921.29M | $12.61 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $900.00M | $48.18 | — |
| TBPH | Theravance Biopharma, Inc. | $884.18M | $17.03 | — |
News headlines (Yahoo Finance, 1h cache)
4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress
2026-09-15 17:12 · Yahoo
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
2026-09-08 11:00 · Yahoo
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
2026-09-06 18:00 · Yahoo
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
2026-08-14 11:00 · Yahoo
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
2026-08-03 11:00 · Yahoo
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
2026-07-16 11:00 · Yahoo
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
2026-07-13 11:00 · Yahoo
H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PT
2026-05-01 08:18 · Yahoo
Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now
2026-04-29 17:00 · Yahoo
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
2026-04-16 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.